Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
STAT15h
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
FiercePharma13h
Taking its best shot at Roche, Merck scores in phase 3 trial of subcutaneous Keytruda
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
Benzinga.com14h
1MRK : Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...
The Pharma Letter8h
Subcutaneous Keytruda meets goals, says Merck
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
BioSpace12h
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...